Sandborn WJ - Search Results

1

Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse.

Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, Vande Casteele N. Papamichael K, et al. Among authors: sandborn wj. Inflamm Bowel Dis. 2015 Jan;21(1):182-97. doi: 10.1097/MIB.0000000000000202. Inflamm Bowel Dis. 2015. PMID: 25222660

2

Medical therapy for induction and maintenance of remission in pouchitis: a systematic review.

Sandborn WJ, McLeod R, Jewell DP. Sandborn WJ, et al. Inflamm Bowel Dis. 1999 Feb;5(1):33-9. doi: 10.1097/00054725-199902000-00005. Inflamm Bowel Dis. 1999. PMID: 10028447 Review.

3

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.

Sandborn WJ, Hanauer SB. Sandborn WJ, et al. Inflamm Bowel Dis. 1999 May;5(2):119-33. doi: 10.1097/00054725-199905000-00008. Inflamm Bowel Dis. 1999. PMID: 10338381 Review.

4

Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate.

Egan LJ, Sandborn WJ, Mays DC, Tremaine WJ, Lipsky JJ. Egan LJ, et al. Among authors: sandborn wj. Inflamm Bowel Dis. 1999 Aug;5(3):167-73. doi: 10.1097/00054725-199908000-00004. Inflamm Bowel Dis. 1999. PMID: 10453372

5

Infliximab for the treatment of orofacial Crohn's disease.

Mahadevan U, Sandborn WJ. Mahadevan U, et al. Among authors: sandborn wj. Inflamm Bowel Dis. 2001 Feb;7(1):38-42. doi: 10.1097/00054725-200102000-00006. Inflamm Bowel Dis. 2001. PMID: 11233659

6

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK. Sands BE, et al. Among authors: sandborn wj. Inflamm Bowel Dis. 2001 May;7(2):83-8. doi: 10.1097/00054725-200105000-00001. Inflamm Bowel Dis. 2001. PMID: 11383595 Clinical Trial.

7

A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease.

Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Löfberg R, Modigliani R, Present DH, Rutgeerts P, Schölmerich J, Stange EF, Sutherland LR. Sandborn WJ, et al. Gastroenterology. 2002 Feb;122(2):512-30. doi: 10.1053/gast.2002.31072. Gastroenterology. 2002. PMID: 11832465 Review. No abstract available.

8

Challenges in IBD Research: updating the scientific agendas.

Elson CO, Sartor RB, Targan SR, Sandborn WJ. Elson CO, et al. Among authors: sandborn wj. Inflamm Bowel Dis. 2003 May;9(3):137-53. doi: 10.1097/00054725-200305000-00001. Inflamm Bowel Dis. 2003. PMID: 12792219 No abstract available.

9

Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.

Thomas CW Jr, Lowry PW, Franklin CL, Weaver AL, Myhre GM, Mays DC, Tremaine WJ, Lipsky JJ, Sandborn WJ. Thomas CW Jr, et al. Among authors: sandborn wj. Inflamm Bowel Dis. 2003 Jul;9(4):237-45. doi: 10.1097/00054725-200307000-00004. Inflamm Bowel Dis. 2003. PMID: 12902847 Clinical Trial.

10

Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease.

Thomas CW Jr, Weinshenker BG, Sandborn WJ. Thomas CW Jr, et al. Among authors: sandborn wj. Inflamm Bowel Dis. 2004 Jan;10(1):28-31. doi: 10.1097/00054725-200401000-00004. Inflamm Bowel Dis. 2004. PMID: 15058523

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

951 results

Search Page

Filters